Immunoglobulin idiotype protein of malignant B cell (Idiotype protein (Id))

The "Immunoglobulin idiotype protein of malignant B cell" refers to the unique set of antigenic determinants (idiotopes) found in the variable region of immunoglobulins expressed by malignant B cells. Each malignant B cell clone in cancers such as lymphoma, leukemia, or myeloma expresses a unique immunoglobulin variable region — the idiotype — that arises from somatic gene rearrangement and mutation. This idiotype can serve as a true tumor-specific antigen as it is clonally restricted to malignant cells and not found on the patient’s healthy B cells. Therapeutically, anti-idiotype strategies exploit this uniqueness: monoclonal antibodies or vaccines generated to target the patient’s specific idiotype induce immune mechanisms (antibody-mediated or T cell-mediated) to selectively eliminate idiotype-positive tumor cells, with anti-idiotype antibodies or T cells recognizing the idiotype as a neoantigen. Hence, the idiotype protein of a malignant B cell is a highly validated, though complex and individualized, immunotherapy target in B cell malignancies. Notes on conventions: The idiotype is not a conventional "receptor" but a structural protein domain/epitope within the B cell receptor (membrane-bound immunoglobulin) or secreted antibody, unique to each B cell clone. "Idiotype" (Id) is the correct technical abbreviation. The canonical form uses singular: "Immunoglobulin idiotype protein of malignant B cell." The target is highly specific for monoclonal B cell populations in malignancy and forms the basis for truly personalized immunotherapies.

Other names

idiotype proteinB cell tumor idiotypetumor-specific idiotypeB cell clonotypic immunoglobulinmalignant B cell idiotypeIg idiotype

Induction of anti-idiotype immune response (immunization triggers anti-Id antibodies or T cell responses against the unique idiotype on malignant B cells); Direct targeting by monoclonal antibodies leading to B cell depletion or tumor cell death